AU4246793A - Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents - Google Patents
Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agentsInfo
- Publication number
- AU4246793A AU4246793A AU42467/93A AU4246793A AU4246793A AU 4246793 A AU4246793 A AU 4246793A AU 42467/93 A AU42467/93 A AU 42467/93A AU 4246793 A AU4246793 A AU 4246793A AU 4246793 A AU4246793 A AU 4246793A
- Authority
- AU
- Australia
- Prior art keywords
- composition
- compound
- intraocular pressure
- calcium
- calcium antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88232892A | 1992-05-13 | 1992-05-13 | |
US882328 | 1992-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU4246793A true AU4246793A (en) | 1993-12-13 |
Family
ID=25380354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU42467/93A Abandoned AU4246793A (en) | 1992-05-13 | 1993-05-12 | Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0639986A1 (ja) |
JP (1) | JPH07508030A (ja) |
AU (1) | AU4246793A (ja) |
CA (1) | CA2131101A1 (ja) |
WO (1) | WO1993023082A1 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686879B1 (fr) * | 1992-02-05 | 1994-03-18 | Adir Cie | Nouveaux composes de 1,4-dihydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant. |
US5922773A (en) * | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
US5756502A (en) * | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
DE4430128A1 (de) * | 1994-08-25 | 1996-02-29 | Hoechst Ag | Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen |
US5733938A (en) * | 1994-09-09 | 1998-03-31 | Allergan | Combination of levobunolol and dipivefrin for topical ophthalmic use |
US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
AU720326B2 (en) | 1995-12-21 | 2000-05-25 | Alcon Laboratories, Inc. | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia |
US6225327B1 (en) | 1996-04-18 | 2001-05-01 | Alcon Laboratories, Inc. | Compounds which inhibit human conjunctival mast cell degranulation for treating ocular allergic-type complications |
WO1997040834A1 (fr) * | 1996-04-26 | 1997-11-06 | Fujisawa Pharmaceutical Co., Ltd. | Agents ameliorant la circulation peripherique pour tissus ophthalmiques contenant des dihydropyridines |
WO1997045118A1 (fr) * | 1996-05-27 | 1997-12-04 | Otsuka Pharmaceutical Co., Ltd. | Agents ameliorant le flux sanguin ophtalmovasculaire et agents protecteurs des papilles optiques |
CA2270119A1 (en) | 1996-10-28 | 1998-05-07 | Senju Pharmaceutical Co., Ltd. | Drugs for ameliorating ocular circulatory disorders |
IT1295423B1 (it) * | 1997-10-10 | 1999-05-12 | Medivis S R L | Uso della flunarizina nella terapia topica del glaucoma |
ES2224597T3 (es) | 1998-01-29 | 2005-03-01 | Akzo Nobel N.V. | Agentes que mejoran la circulacion optica papilar. |
WO2000057914A1 (fr) * | 1999-03-25 | 2000-10-05 | Santen Pharmaceutical Co., Ltd. | Agents permettant d'abaisser la tension oculaire |
US6482854B1 (en) | 1999-03-25 | 2002-11-19 | Massachusetts Eye And Ear Infirmary | Glaucoma treatment |
CA2369299A1 (en) * | 1999-04-14 | 2000-10-19 | Senju Pharmaceutical Co., Ltd. | Inhibitor of visual function disturbance caused by optic nerve cell disorder due to factor other than ophthalmic circulatory disorder |
WO2001041756A2 (en) * | 1999-12-02 | 2001-06-14 | University Of South Florida | Method and composition for treatment of ischemic neuronal reperfusion injury |
EP1265903B1 (en) * | 2000-03-23 | 2004-05-12 | Ortho-Mcneil Pharmaceutical, Inc. | Thiepino[3,2-b]dihydropyridines and related compositions and methods |
WO2001092267A2 (en) * | 2000-05-30 | 2001-12-06 | Ortho-Mcneil Pharmaceutical, Inc. | Dihydropyridine compounds for the inhibition of calcium-influx |
EP1426051B1 (en) * | 2001-09-11 | 2008-07-16 | Asahi Kasei Pharma Corporation | Medicinal composition for prevention of or treatment for cerebrovascular disorder |
TW200306839A (en) * | 2002-02-06 | 2003-12-01 | Novartis Ag | Quinazolinone derivatives and their use as CB agonists |
US20050176822A1 (en) * | 2002-03-28 | 2005-08-11 | Naoto Hanyu | Phenylacetonitrile derivatives and hair tonics and external preparations for skin containing the derivatives |
WO2004045644A1 (ja) | 2002-11-18 | 2004-06-03 | Santen Pharmaceutical Co., Ltd. | Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 |
WO2004069275A1 (ja) * | 2003-02-04 | 2004-08-19 | Mitsubishi Pharma Corporation | 眼科用剤 |
JP5576659B2 (ja) * | 2006-12-05 | 2014-08-20 | ザ ロイヤル インスティテューション フォー ジ アドバンスメント オブ ラーニング/ マギル ユニバーシティ | Trkレセプター調節因子の使用方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4911920A (en) * | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
FR2577802B1 (fr) * | 1985-02-26 | 1987-07-24 | Synthelabo | Compositions pharmaceutiques a base de betaxolol et de nifedipine |
FR2585574B1 (fr) * | 1985-07-31 | 1988-09-09 | Corbiere Jerome | Nouvelles compositions pharmaceutiques anti-glaucomateuses a base de 1,4-dihydropyridines et leur procede d'obtention |
FR2593395A1 (fr) * | 1986-01-28 | 1987-07-31 | Corbiere Jerome | Nouvelles compositions pharmaceutiques antiglaucomateuses a base de 3-acetoxy-5-(2-dimethylaminoethyl)-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepine-4-one ou d'un de ses sels et leur procede d'obtention |
US4981871A (en) * | 1987-05-15 | 1991-01-01 | Abelson Mark B | Treatment of ocular hypertension with class I calcium channel blocking agents |
JP2536806B2 (ja) * | 1991-03-27 | 1996-09-25 | アルコン ラボラトリーズ インコーポレイテッド | ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物 |
-
1993
- 1993-05-12 EP EP93911276A patent/EP0639986A1/en not_active Withdrawn
- 1993-05-12 WO PCT/US1993/004505 patent/WO1993023082A1/en not_active Application Discontinuation
- 1993-05-12 AU AU42467/93A patent/AU4246793A/en not_active Abandoned
- 1993-05-12 CA CA002131101A patent/CA2131101A1/en not_active Abandoned
- 1993-05-12 JP JP6503718A patent/JPH07508030A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO1993023082A1 (en) | 1993-11-25 |
EP0639986A1 (en) | 1995-03-01 |
CA2131101A1 (en) | 1993-11-25 |
JPH07508030A (ja) | 1995-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU4246793A (en) | Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents | |
EP0868186B1 (en) | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia | |
EP0664707B1 (en) | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma | |
JP2732312B2 (ja) | アルファ‐2作用薬及びベータ遮断薬の組合せを含む抗緑内障組成物 | |
WO1995026711A1 (en) | Ophthalmic composition with decreased viscosity | |
HU223070B1 (hu) | Ionérzékeny, hidrofil polimert és szervetlen sót viszkozitáscsökkenést eredményező arányban tartalmazó szemészeti készítmény | |
AU704938B2 (en) | Combination therapy for treating glaucoma | |
AU3082999A (en) | Combination therapy for treating glaucoma | |
US6172054B1 (en) | Combination therapy for lowering and controlling intraocular pressure | |
JP2004182723A (ja) | Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 | |
US4734438A (en) | Norepinephrine potentiated compositions and method of use | |
EP0625903B1 (en) | Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers | |
CA2240271C (en) | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia | |
AU2001217709B2 (en) | Combination therapy for lowering and controlling intraocular pressure | |
WO1998014193A1 (en) | The use of a substance p antagonist for the manufacture of a medicament for the treatment of ocular pain | |
AU2001217709A1 (en) | Combination therapy for lowering and controlling intraocular pressure | |
EP0728480A1 (en) | Use of ifenprodil for treatment of elevated intraocular pressure | |
EP0277814B1 (en) | Anti-glaucoma use of trifluoromethanesulfonamide | |
AU2006200143B2 (en) | Combination therapy for lowering and controlling intraocular pressure | |
AU2004214563A1 (en) | Combination therapy for treating glaucoma |